Skip to main content

Advertisement

Fig. 6 | Journal of Biomedical Science

Fig. 6

From: Mode of action of granulocyte-colony stimulating factor (G-CSF) as a novel therapy for stroke in a mouse model

Fig. 6

Effect of G-CSF on expression of Bak and PUMA in BCAO stroke model. a Bak expression in the frontal (F (2, 9) = 34.77, p < 0.0001) and middle (F (2, 12) = 20.85, p = 0.0001) region of BCAO brain were analyzed by Western blot. b Bcl-2/Bak ratio expression in the frontal (F (2, 9) = 67.67, p < 0.0001) and middle (F (2, 12) = 71.9, p < 0.0001) region of BCAO in G-CSF treated group markedly increased versus vehicle treated BCAO group. Treatment of G-CSF significantly decreased Bak level (a) in comparison to the vehicle treated BCAO group. c Western blot analyses showed that G-CSF treatment group has no significant effect on PUMA expression in the ischemic frontal (F (2, 11) = 0.6084, p = 0.5616) and middle (F (2, 10) = 0.04798, p = 0.9534) regions of mouse’s brain on day 7. d Bcl-2/PUMA ratio expression in the frontal (F (2, 11) = 22.07, p = 0.0001) and middle (F (2, 12) = 12.26, p = 0.0013) region of BCAO in G-CSF treated group markedly increased versus vehicle treated BCAO group. Representative western blots are presented with cropped blot panels showing target protein signals and control (GAPDH) protein signals in separate panels derived from the same gel. Values in the graphs represent mean ± SEM. * and # significant compared to sham & vehicle treated groups, respectively by ANOVA and Tukey post hoc tests (n = 5, p < 0.05)

Back to article page